A weekly podcast discussion about asymmetric learning - how organisations gain competitive advantage through their approach to learning, in all its forms. We will talk with thought leaders and experts to understand processes and systems of learning that lead to outperformance.
All content for IDEA Collider is the property of IDEA Pharma and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
A weekly podcast discussion about asymmetric learning - how organisations gain competitive advantage through their approach to learning, in all its forms. We will talk with thought leaders and experts to understand processes and systems of learning that lead to outperformance.
We are excited to tell you more about the IDEA Pharma and Exploristics partnership.
IDEA’s COO, Jacqui Barendregt, asked Exploristics Founder and CEO Aiden Flynn five key questions about the innovative service model and, most importantly, the value to the pharmaceutical industry this newly formed partnership will bring.
In this engaging conversation, we delve into the world of pharmaceutical innovation and collaboration. Our guest, Dr. Nedim Pipic, a pharmaceutical expert specializing in mental and retinal health, shares his journey and passion for making a difference.
Quitting is a valuable skill. It’s important for dealing with uncertainty, yet we are quite bad at exercising it. It should not be just about sticking to things. Quitting is also good, particularly when we have to start most things. Persisting at something when it’s worthwhile is definitely a good character trait but persisting at something when it’s no longer worthwhile is not a good character trait. Calibrate around the notion, “is it worthwhile to stick? "
The speed of Recursion is remarkable in delivering a value proposition. Michael Secora, Chief Financial Officer at Recursion, expounds on data relatability, building various data sets, and leveraging data sets to build a next-generation biopharmaceutical company! Moreover, he shares tips on standing out amongst competitors and what differentiates Recursion from other AI discovery companies.
An interview with Kabir Nath, President & CEO, Otsuka North America Pharmaceutical Business, covering innovation, Kabir's personal journey, culture, technology, books and more...
An interview with Dr Kat Arney, author of Rebel Cell
(Note: some sensitive language content)
Many of us think of cancer as a contemporary killer, a disease of our own making caused by our modern lifestyles. But, as Kat Arney explains in her new book REBEL CELL: Cancer Evolution and the Science of Life, that perception just isn’t true.
A weekly podcast discussion about asymmetric learning - how organisations gain competitive advantage through their approach to learning, in all its forms. We will talk with thought leaders and experts to understand processes and systems of learning that lead to outperformance.
